142 related articles for article (PubMed ID: 57022)
1. Human glomerulonephritis and the C3 nephritic factor (C3NeF).
Berthoux FC; Carpenter CB; Freyria AM; Traeger J; Merrill JP
Clin Nephrol; 1976 Mar; 5(3):93-100. PubMed ID: 57022
[No Abstract] [Full Text] [Related]
2. The C3 nephritic factor (C3NeF) and the heat labile complement inactivator (HLCI) in chronic hypocomplementemic mesangioproliferative glomerulonephritis.
Berthoux FC; Carpenter CB; Traeger J; Merrill JP
Adv Nephrol Necker Hosp; 1974; 4():91-108. PubMed ID: 4220002
[No Abstract] [Full Text] [Related]
3. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
4. Transfer of C3 nephritic factor from mother to fetus. Is C3 nephritic factor IgG?
Davis AE; Arnaout MA; Alper CA; Rosen FS
N Engl J Med; 1977 Jul; 297(3):144-5. PubMed ID: 865586
[No Abstract] [Full Text] [Related]
5. Classical complement pathway activation in membranoproliferative glomerulonephritis.
Ooi YM; Vallota EH; West CD
Kidney Int; 1976 Jan; 9(1):46-53. PubMed ID: 781380
[TBL] [Abstract][Full Text] [Related]
6. Studies of serum complement in the hypocomplementaemic nephritides.
Williams DG; Peters DK; Fallows J; Petrie A; Kourilsky O; Morel-Maroger L; Cameron JS
Clin Exp Immunol; 1974 Nov; 18(3):391-405. PubMed ID: 4219908
[TBL] [Abstract][Full Text] [Related]
7. Nephritic factor, C3 splitting activity, C3 and factor B breakdown products in glomerular diseases.
De Vecchi A; Montagnino G; Scalia P; Tarantino A
Ric Clin Lab; 1980; 10(1):93-7. PubMed ID: 6781054
[No Abstract] [Full Text] [Related]
8. Mesangiocapillary glomerulonephritis and persistent hypocomplementemia.
Cameron JS; Ogg CS; Turner DR; Weller RO; White RH; Glasgow EF; Peters DK; Martin A
Perspect Nephrol Hypertens; 1973; 1 Pt 1():541-56. PubMed ID: 4220250
[No Abstract] [Full Text] [Related]
9. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.
Adam C; Williams DG; Peters DK
Clin Exp Immunol; 1975 Nov; 22(2):240-8. PubMed ID: 813932
[TBL] [Abstract][Full Text] [Related]
11. C3 nephritic factor and hypocomplementaemia in a clinically healthy individual.
Gewurz AT; Imherr SM; Strauss S; Gewurz H; Mold C
Clin Exp Immunol; 1983 Oct; 54(1):253-8. PubMed ID: 6616970
[TBL] [Abstract][Full Text] [Related]
12. Studies of the alternate pathway in chelated serum.
Forsgren A; Mclean RH; Michael AF; Quie PG
J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816
[TBL] [Abstract][Full Text] [Related]
13. Isolation of alternative pathway C3 convertase containing uncleaved B and formed in the presence of C3 nephritic factor (C3neF).
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Feb; 116(2):568-70. PubMed ID: 1249423
[No Abstract] [Full Text] [Related]
14. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
Perrin LH; Lambert PH; Miescher PA
J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
[TBL] [Abstract][Full Text] [Related]
15. Renal transplantation in mesangioproliferative glomerulonephritis (MPGN): relationship between the high frquency of recurrent glomerulonephritis and hypocomplementemia.
Berthoux FC; Ducret F; Colon S; Blanc-Brunat N; Zech PY; Traeger J
Kidney Int Suppl; 1975 Feb; (3):323-7. PubMed ID: 1099312
[No Abstract] [Full Text] [Related]
16. [Complement activating factors in hypocomplementemic membranoproliferative glomerulonephritis (MPGN) patients' sera--comparison with C3NeF positive and negative cases].
Ohmori F; Ohi H; Seki M; Watanabe S; Hatano M
Nihon Jinzo Gakkai Shi; 1987 Apr; 29(4):493-8. PubMed ID: 3656707
[No Abstract] [Full Text] [Related]
17. Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus.
Arroyave CM; Wilson MR; Tan EM
J Immunol; 1976 Mar; 116(3):821-6. PubMed ID: 815434
[TBL] [Abstract][Full Text] [Related]
18. Evidence for activation of the alternate pathway in glomerulonephritis.
Michael AF; McLean RH
Adv Nephrol Necker Hosp; 1974; 4():49-66. PubMed ID: 4219999
[No Abstract] [Full Text] [Related]
19. Quantitative measurement of properdin in normal human serum by electroimmunoassay and single radial immunodiffusion.
Persson K; Kindmark CO; Pensky J; Naff G
Clin Exp Immunol; 1977 Jul; 29(1):84-8. PubMed ID: 408067
[TBL] [Abstract][Full Text] [Related]
20. A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.
Vallota EH; Götze O; Spiegelberg HL; Forristal J; West CD; Müller-Eberhard HJ
J Exp Med; 1974 May; 139(5):1249-61. PubMed ID: 4207623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
